Professor Barenholz will discuss the current developments in the Israeli BioMed-Health industries and will share his experience as an inventor and entrepreneur in the development of the anti-cancer drug Doxil, which is the first Nano-drug approved by the FDA. Now Doxil (brand name of Caelyx in Europe) was used for the treatment of 600,000 patients worldwide with sales that exceeds $10 Billion.
Prof. Yechezkel (Chezy) Barenholz, is the Head of the Membrane and Liposome Research Lab at the Hebrew University‐Hadassah Medical School, and is a renowned specialist in biochemistry, biophysics, nanotechnology and cancer. His applied research focuses on amphiphile-based drug carriers, especially liposomes, from basic design of the drug carriers through clinical trials and development of FDA-approved drugs. Prof. Barenholz is the Founder of several prominent start-up companies, including Moebius Medical. He is co-inventor of the first FDA-approved nano drug, DOXIL® , which is used extensively to treat ovarian and breast cancer. Prof. Barenholz has been a Visiting Professor at many universities throughout the world, including the University of Virginia School of Medicine; University of Utrecht; University of Kyoto, Japan; and La Sapeinza University, Rome. He is also founder of several prominent startup companies, including NasVax Ltd. and clinical stage Moebius Medical. Prof. Barenholz is a coauthor of more than 380 scientific publications, and a co‐inventor of over 30 approved patent families. Prof. Barenholz also serves also as the head of the advisory board of Israel’s first MBA program in biomedical Management and entrepreneurship (BioMed-MBA) which was launched 2 years ago at the Hebrew University.